Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1984 1
1988 1
2000 1
2009 3
2010 1
2014 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.
Mjaavatten MD, van der Heijde D, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK. Mjaavatten MD, et al. Among authors: helgetveit k. Arthritis Res Ther. 2010;12(3):R76. doi: 10.1186/ar2995. Epub 2010 May 5. Arthritis Res Ther. 2010. PMID: 20444271 Free PMC article.
Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort.
Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK. Mjaavatten MD, et al. Among authors: helgetveit k. Arthritis Res Ther. 2009;11(5):R146. doi: 10.1186/ar2820. Epub 2009 Oct 1. Arthritis Res Ther. 2009. PMID: 19796386 Free PMC article.
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E. Day R, et al. Among authors: helgetveit kb. Arch Intern Med. 2000 Jun 26;160(12):1781-7. doi: 10.1001/archinte.160.12.1781. Arch Intern Med. 2000. PMID: 10871971 Clinical Trial.
11 results